{"id":918454,"date":"2025-12-10T14:03:01","date_gmt":"2025-12-10T19:03:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/"},"modified":"2025-12-10T14:03:01","modified_gmt":"2025-12-10T19:03:01","slug":"maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/","title":{"rendered":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>CHICAGO, Dec.  10, 2025  (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology (NYSE American: MAIA) \u2013<\/b> The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class\u2014telomere-targeting agents\u2014is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy.<\/p>\n<p align=\"justify\">This is a segment that existing therapies leave behind. And it is the segment where we believe that ateganosine, developed by MAIA, may soon become one of the most consequential entrants in years.<\/p>\n<p align=\"justify\">\n        <b>A Market Dominated by Checkpoint Inhibitors\u2014But Vulnerable at Its Edges<\/b>\n      <\/p>\n<p align=\"justify\">CPI therapies remain the backbone of NSCLC treatment in patients who don\u2019t have an actionable mutation. Collectively, the category generated approximately $50 billion in global sales in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_I2yC2SPQs6G7v-4cDTW6KoZPfE-JLej4DH1CITZcXrB3hHCXhU0F93NiwJREAztjiFKTztv52otvE9IhPQp45ZnfNVSq0ja9KyRIyPwCm3G-yikgzFGe8EjNBSFtYEsmO51vRpXzUlFh38YtEj8hlcm8PhrLL2ExAXjiVz0fVNXpwoYygBhHHIE--SgRYTK\" rel=\"nofollow\" target=\"_blank\">2024<\/a>, anchored by five major agents approved for NSCLC. The therapeutic concentration in lung cancer is striking:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">&gt;30% of all NSCLC drug sales come from CPIs<\/li>\n<li style=\"text-align:justify\">&gt;40% of all CPI global sales originate from NSCLC alone<\/li>\n<\/ul>\n<p align=\"justify\">Merck\u2019s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by 2027\u2014just before biosimilars begin entering the market in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tyf1HfwgCHB7QPtbo33Lt9DHWWu74YbCjAr8qf7smpcDObMc42nypK1fDVWT2GMbXGEl1NUZFg40I_PVi0xPtT6Yt2-Fu168GZmi_spHKQXfdvi2RAuwdUuT4l7tC4BSktQAZ9dL_5HWP3PlVpe_OaJDcymyLZMdQD_N32oqAfI=\" rel=\"nofollow\" target=\"_blank\">2028<\/a>.<\/p>\n<p align=\"justify\">While CPIs have transformed outcomes for some patients, in our opinion their limitations remain clear: patients without actionable mutations, and those who become CPI-refractory, still experience extremely poor prognosis and limited therapeutic benefit. We believe this treatment gap has become one of the industry\u2019s largest unmet needs.<\/p>\n<p align=\"justify\">\n        <b>Telomere-Targeting: A New Pathway for a Hard-to-Treat Population<\/b>\n      <\/p>\n<p align=\"justify\">We believe that MAIA\u2019s ateganosine represents the first drug in a new class. Unlike targeted therapies requiring EGFR, ALK, KRAS, or other mutations\u2014and unlike immunotherapies dependent on PD-1\/PD-L1 dynamics\u2014ateganosine has been designed to exploit a universal feature of cancer cells: telomerase activity, present in more than 80% of human tumors.<\/p>\n<p align=\"justify\">Its dual mechanism has been designed to disrupt telomeres to trigger direct cancer cell death while simultaneously enabling the immune system to respond to cancer. MAIA was recently awarded Fast Track Designation by the U.S. FDA for the treatment of NSCLC in patients resistant to immunotherapy and chemotherapy, and is initiating a Phase 3 THIO-104 trial.<\/p>\n<p align=\"justify\">\n        <b>A Commercial Opportunity That Extends Across Oncology<\/b>\n      <\/p>\n<p align=\"justify\">With the NSCLC market now valued at $34.1 billion\u2014projected to nearly double to $68.8 billion by 2033\u2014the implications of a first-in-class therapy are substantial. In the United States alone, roughly <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=guPxmY2Br3OcnkgaP-SXeKF0vd4KwVhl5RsgszM46nWxBk4yL8tr7mubXp3F97xa99CEdVOi7GyyY488XrflZ-rROBRPk555mc0Vk-_opRgQZVGkldrZ-Pf20vhWy6PIfTRSGxTkmmAfhPruBht4CCJHU0jSX9aLx52DIzYuI2YDct70gCeA7ygirlyfvmCNgvVM2Ke6mqy78CvBQ6uGTmGGyofbkk3aDiwmgKIRZt2fuE7enZq2u3I73r1zour4cdBe29nTcWkD9xwHvhyOYQ==\" rel=\"nofollow\" target=\"_blank\">180,000 patients enter the NSCLC treatment ecosystem<\/a> every year.<\/p>\n<p align=\"justify\">But ateganosine\u2019s opportunity does not end with lung cancer. The candidate already carries FDA Orphan Drug Designations (ODDs) for:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Glioblastoma (market: $2.2B \u2192 $3.2B growth expected)<\/li>\n<li style=\"text-align:justify\">Hepatocellular carcinoma (HCC) (mortality: 0.8M; sales: $3.8B)<\/li>\n<li style=\"text-align:justify\">Small cell lung cancer (SCLC) (mortality: 0.3M; sales: $2.8B)<\/li>\n<\/ul>\n<p align=\"justify\">Each ODD offers seven years of U.S. market exclusivity upon regulatory FDA approval and access to tax credits\u2014advantages that strengthen MAIA\u2019s long-term market positioning.<\/p>\n<p align=\"justify\">\n        <b>A Strategic Inflection Point for the Entire NSCLC Treatment Landscape<\/b>\n      <\/p>\n<p align=\"justify\">The oncology market is poised for a shift as developers seek to fill in gaps in the treatment landscape. The next decade is expected to reward novel mechanisms, and in our opinioin advanced NSCLC represents the clearest example of that gap.<\/p>\n<p align=\"justify\">Telomere-targeting therapeutics may be the next foundation in that evolution. If ateganosine\u2019s outcomes are successful, the therapy could become a defining entrant in a space where treatment failure has long been accepted as inevitable. Statistical assessments points to a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H5FP-uELEWXHmUZKznOtQPQcUl0tu3cjT_B_4j1gRZ6nDMdASSz_MqKvTS7lhQSVdbbUvODVlPSo-dhJ4R6IzXgZ5jNQdKLKsme_8i3i1lk7ARl5l9KFBnEiS8OHzLSjRokGJ_6JnrFyStuBCzpPNI34gGQLjsdb49JUZeCMfwRyK9P7lVjGPolhNZfskYAkAFoN41VgmwZaCIm8vCWFhrHx8ul2Z4IrQhtnvDJFCJo=\" rel=\"nofollow\" target=\"_blank\">high probability of technical success<\/a> for regulatory approval of ateganosine.<\/p>\n<p align=\"justify\">In our opinion, MAIA is now positioned at the center of this turning point\u2014scientifically and strategically.<\/p>\n<p align=\"justify\">\n        <b>About MAIA Biotechnology, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L0OWViXlQnrybSW61Aa6A0Z3RptxVMBkC2s4UKCPxudacZ_Qi6jpnzw9WTGYSCMMPTr5pVPqXrM2MA2giKkIIUNDE3qVeUZoBlAWX56TvfQ=\" rel=\"nofollow\" target=\"_blank\">www.maiabiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements <\/b>\n      <\/p>\n<p align=\"justify\">MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, \u201cMAIA,\u201d \u201cCompany,\u201d \u201cwe,\u201d \u201cour,\u201d and \u201cus\u201d refers to MAIA Biotechnology, Inc. and its subsidiaries.<\/p>\n<p>\n        <b>Investor Relations Contact<\/b><br \/>\n        <br \/>+1 (872) 270-3518<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uWHRyMngD7Zyoh5FomzrkogpdMuSUtAi0PIrv9oPuH9QCNwtQX5CLGF1_BLpujTM6IG9-s2a6wfRJzWQkigzjEsqQihm7IX9pS6Kg9a0Zuk=\" rel=\"nofollow\" target=\"_blank\">ir@maiabiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDNmOGU3MDAtMTA0OC00Y2Y5LWE2NDAtYmNhZjcwZTcwZWNmLTUwMDEyMjI1Ny0yMDI1LTEyLTEwLWVu\/tiny\/MAIA-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology (NYSE American: MAIA) \u2013 The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class\u2014telomere-targeting agents\u2014is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy. This is a segment that existing therapies leave behind. And it is the segment where we believe that ateganosine, developed by MAIA, may soon become one of the most consequential entrants in years. A Market Dominated by Checkpoint Inhibitors\u2014But Vulnerable at Its Edges CPI therapies remain the backbone of NSCLC treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-918454","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology (NYSE American: MAIA) \u2013 The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class\u2014telomere-targeting agents\u2014is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy. This is a segment that existing therapies leave behind. And it is the segment where we believe that ateganosine, developed by MAIA, may soon become one of the most consequential entrants in years. A Market Dominated by Checkpoint Inhibitors\u2014But Vulnerable at Its Edges CPI therapies remain the backbone of NSCLC treatment &hellip; Continue reading &quot;MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T19:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach\",\"datePublished\":\"2025-12-10T19:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/\"},\"wordCount\":1081,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/\",\"name\":\"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\",\"datePublished\":\"2025-12-10T19:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk","og_description":"CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology (NYSE American: MAIA) \u2013 The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class\u2014telomere-targeting agents\u2014is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy. This is a segment that existing therapies leave behind. And it is the segment where we believe that ateganosine, developed by MAIA, may soon become one of the most consequential entrants in years. A Market Dominated by Checkpoint Inhibitors\u2014But Vulnerable at Its Edges CPI therapies remain the backbone of NSCLC treatment &hellip; Continue reading \"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-10T19:03:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach","datePublished":"2025-12-10T19:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/"},"wordCount":1081,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/","name":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==","datePublished":"2025-12-10T19:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDIxNiM3MzE2MTQ0IzUwMDEyMjI1Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-takes-aim-at-a-50b-immunotherapy-market-with-breakthrough-telomere-targeting-approach\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=918454"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=918454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=918454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=918454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}